Shares of Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY – Get Free Report) dropped 6.2% during mid-day trading on Tuesday . The company traded as low as $11.26 and last traded at $11.26. Approximately 291 shares were traded during trading, a decline of 97% from the average session volume of 9,756 shares. The stock had previously closed at $12.01.
Santen Pharmaceutical Trading Down 2.2%
The company has a fifty day moving average of $12.52 and a 200 day moving average of $11.69.
Santen Pharmaceutical Company Profile
Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.
With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.
Featured Stories
- Five stocks we like better than Santen Pharmaceutical
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for Santen Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santen Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
